MENU

HIMS Hims & Hers Health Forecast, Technical & Fundamental Analysis

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss... Show more

A.I.Advisor
Nov 17, 2026

Hims & Hers Health (HIMS) Stock Forecast: Can the Branded Weight-Loss Pivot Reignite Profitability?

Key Takeaways

  • Branded GLP-1 transition is the defining catalyst: Following agreements with Novo Nordisk and Eli Lilly, Hims & Hers is shifting from high-margin compounded weight-loss drugs to lower-margin branded products, a trade-off between revenue durability and profitability.
  • Margin recovery is the central question: Gross margin has compressed from roughly 74% to around 57%, and management has guided for a return to net profitability only in 2027, making cost discipline a key focus for investors.
  • International expansion is a structural growth lever: The company is scaling in the UK, Germany, and Australia (including its Eucalyptus acquisition), positioning for long-term market diversification beyond the U.S.
  • Regulatory and legal scrutiny remains a swing factor: FDA guidance on compounded peptides, Federal Trade Commission oversight of subscription practices, and state-level corporate-practice-of-medicine rules could shape the platform's economics.
  • Analyst consensus is cautious but not bearish: The Street largely rates HIMS a "Hold," with price targets concentrated in the high-$20s to low-$30s and a wide spread between bullish and bearish estimates.
  • For more detail on the company's developments, explore Major News, Today's Price Move, Price Targets, and Earnings on Tickeron's dedicated pages.
  • To complement your research with AI-driven insights, explore Trending AI Robots.

Strategic Positioning and Competitive Outlook

Hims & Hers Health has built one of the largest direct-to-consumer telehealth platforms in the U.S., with nearly 2.8 million subscribers spanning sexual health, dermatology, mental health, hormone therapy, and weight management. Its competitive advantage rests on a vertically integrated, personalized-care model that pairs telehealth providers, branded and compounded medications, and, increasingly, in-house lab testing.

The company's medium-term positioning hinges on its pivot within weight loss. After the U.S. Food and Drug Administration (FDA) declared the GLP-1 (glucagon-like peptide-1) shortage over in early 2026, the economics of compounding changed, forcing Hims to reorient toward branded therapies. Distribution agreements with Novo Nordisk and Eli Lilly give the platform access to Wegovy, Zepbound, and Foundayo, preserving its relevance in obesity care while compressing margins. In parallel, management is diversifying into peptides, testosterone, and menopause offerings, and expanding internationally to reduce reliance on any single U.S. product category.

Major Catalysts Ahead

  • Fourth-quarter and full-year 2026 earnings: The next report will test whether the branded GLP-1 and peptide ramps can offset margin pressure and subscriber churn, following a quarter in which subscribers dipped modestly amid deliberately paced marketing.
  • Peptides+ rollout: Newly launched products such as BPC-157 and TB-500 represent a higher-margin growth vector, though management has signaled revenue contribution will remain immaterial through 2026 and ramp into 2027.
  • Eli Lilly partnership integration: Bringing Zepbound onto the platform at self-pay prices broadens the addressable market, but its economics are thinner than legacy compounded offerings.
  • Regulatory decisions: FDA standards for compounded peptides and ongoing FTC (Federal Trade Commission) and state-level scrutiny of subscription and corporate-practice structures could materially affect margins and growth.
  • Analyst sentiment trends: Consensus has settled into a "Hold" posture, with average price targets in the high-$20s and notable dispersion—bullish firms such as Needham and Barclays sit well above cautious targets from banks like Morgan Stanley and BofA Securities—reflecting genuine uncertainty about the profit trajectory.

Industry and Macroeconomic Forces

The company's trajectory is closely tied to the broader obesity and digital-health market, where demand for GLP-1 therapies remains robust but pricing is becoming more competitive as major pharmaceutical makers expand direct-to-consumer access. Interest-rate and inflation dynamics matter through their effect on discretionary consumer spending and customer acquisition costs, which have risen on dominant advertising platforms.

Regulatory climate is arguably the most consequential macro variable. The FDA's stance on compounding and peptides directly determines which products Hims can legally and profitably offer, while evolving telehealth and subscription rules could raise compliance costs. Meanwhile, international expansion into markets such as the UK and Australia introduces currency, reimbursement, and competitive factors distinct from the U.S. model.

Trend Prediction Engine

Investors seeking a forward-looking lens on HIMS may turn to Tickeron's Trend Prediction Engine, an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. The engine is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. It offers searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. Exploring these AI-driven signals can complement fundamental analysis when assessing a fast-evolving name like Hims & Hers.

2026 Outlook and Long-Term Themes to Watch

Looking into 2026 and beyond, Hims & Hers is navigating a deliberate transition from a high-margin, single-product growth story toward a diversified, multi-market healthcare platform. Management has maintained long-term ambitions of roughly $6.5 billion in revenue and $1.3 billion in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) by 2030, but the near-term path involves compressed margins and negative operating leverage as branded drugs and international operations scale.

Key themes to monitor include whether margin sustainability improves as branded cohorts compound and retention strengthens, whether the peptide and testosterone categories deliver higher-margin growth, and whether international expansion achieves profitability without excessive acquisition and marketing costs. Competitive threats from incumbent telehealth players and direct-to-consumer offerings from pharmaceutical giants, as well as any tightening of regulatory oversight, represent the principal risks to the long-term outlook. Consensus analyst expectations remain measured, with price targets implying a wide range of outcomes that reflect both the platform's demonstrated top-line momentum and unresolved questions about its path back to sustainable profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published Earnings

HIMS is expected to report earnings to rise 285.67% to 11 cents per share on March 01

Hims & Hers Health HIMS Stock Earnings Reports
Q4'26
Est.
$0.12
Q3'26
Missed
by $0.04
Q2'26
Missed
by $0.32
Q1'26
Missed
by $0.41
Q4'25
Beat
by $0.03
The last earnings report on November 09 showed earnings per share of 2 cents, missing the estimate of 7 cents. With 16.13M shares outstanding, the current market capitalization sits at 6.07B.
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TCPB49.090.26
+0.53%
Thrivent Core Plus Bond ETF
CPRJ27.13-0.06
-0.22%
Calamos Russell 2000 Structured Alt Protection ETF July (CPRJ)
FEMV26.08-0.59
-2.22%
Fidelity Enhanced Mid Cap Value ETF (FEMV)
SHDG31.28-0.72
-2.24%
Soundwatch Hedged Equity ETF (SHDG)
VTHR304.86-10.82
-3.43%
Vanguard Russell 3000 ETF (VTHR)

HIMS and Stocks

Correlation & Price change

A.I.dvisor tells us that HIMS and COTY have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HIMS and COTY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HIMS
1D Price
Change %
HIMS100%
-8.86%
COTY - HIMS
31%
Poorly correlated
-2.47%
HROW - HIMS
29%
Poorly correlated
-5.35%
AYTU - HIMS
28%
Poorly correlated
N/A
DERM - HIMS
25%
Poorly correlated
-7.04%
IRWD - HIMS
25%
Poorly correlated
-0.21%
More

Groups containing HIMS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HIMS
1D Price
Change %
HIMS100%
-8.86%
Pharmaceuticals: Generic
industry (81 stocks)
14%
Poorly correlated
-3.61%
Pharmaceuticals
industry (151 stocks)
12%
Poorly correlated
-3.32%
A.I. Advisor
published General Information

General Information

a company, which is involved in real estate investment trusts

Industry PharmaceuticalsGeneric

Industry
N/A
Address
2269 Chestnut Street
Phone
+1 415 851-0195
Employees
2442
Web
https://www.forhims.com
Hims & Hers Health (HIMS) Stock Forecast: Can the Branded Weight-Loss Pivot Reignite Profitability?